P190022/S003: 4Kscore Test
FDA’s recorded scope: Approval for the addition of the DRE Unavailable variant as part of the 4KScore Test system
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 1 FDA record to the applicant name Opko Health, Inc.. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jul 25, 2025 to Jul 25, 2025. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code QRF appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P190022, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 4400 Biscayne Blvd., Miami, FL, 33137. Recorded on P190022/S003, decision dated Jul 25, 2025.
Multi-analyte test system with algorithmic analysis for detection of prostate cancer.
FDA’s recorded scope: Approval for the addition of the DRE Unavailable variant as part of the 4KScore Test system
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
4Kscore TestP190022/S003 | Opko Health, Inc. | PMA supplement | Jul 25, 2025 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.